(VSTM) Verastem, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VSTM) Verastem, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Verastem, Inc. 4P's Marketing Mix Analysis summarizes the company’s Product, Price, Place, and Promotion strategy so you can see how its oncology portfolio is positioned and marketed; the page includes a real preview/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to get the complete ready-to-use report.
Product
VS-6766 dual RAF/MEK inhibitor
Verastem’s lead product, VS-6766, is a dual RAF/MEK inhibitor that uses a clamp mechanism to block MEK kinase activity and RAF-driven MEK phosphorylation. As of July 2026, it remains the company’s core platform asset in its pipeline and market story. Its main value is clinical differentiation in RAS/MAPK-driven cancers, where Verastem is still built around this single lead program.
Defactinib oral FAK inhibitor
Defactinib is an oral small-molecule focal adhesion kinase inhibitor, and Verastem pairs it with VS-6766 in multiple studies. In 2025, this 2-drug strategy helped widen the oncology pipeline beyond a single asset and support a more durable franchise. It also gives Verastem more than 1 path to value creation.
RAMP 201 recurrent LGSOC
RAMP 201 is a multicenter, randomized, open-label study testing VS-6766 alone and with defactinib in recurrent low-grade serous ovarian cancer. It supports Verastem, Inc.'s product validation by checking both tumor response and combination value in a hard-to-treat niche. The readout can sharpen Verastem, Inc.'s positioning for a rare cancer with limited standard options.
RAMP 202 NSCLC KRAS and BRAF
RAMP 202 is Verastem, Inc.'s Phase 2 study of VS-6766 plus defactinib in NSCLC with KRAS or BRAF mutations after platinum-based therapy and immune checkpoint inhibitors. It targets a small, genetically defined oncology group, which can improve trial precision and commercial focus. Phase 2 data matter here because the setting is late-line, mutation-selected lung cancer, where response signals can support the 4P "Product" case.
- Phase 2: RAMP 202
- Combo: VS-6766 + defactinib
- Population: KRAS/BRAF NSCLC
- Setting: post-platinum, post-ICI
RAMP 203 VS-6766 plus LUMAKRAS
RAMP 203 pairs Verastem, Inc.’s VS-6766 with Amgen’s LUMAKRAS in a Phase 1/2 study, testing a KRAS-G12C inhibitor plus a RAF/MEK clamp in solid tumors. It pushes Verastem, Inc. deeper into combination-based precision oncology, where response depth and resistance control matter most. The combo strategy can widen the commercial use case beyond monotherapy.
- Phase 1/2 combo trial
- VS-6766 plus LUMAKRAS
- Targets KRAS-driven tumors
- Expands precision oncology reach
Verastem’s Narrow but Focused 2025-2026 Pipeline
Verastem’s Product mix in 2025-2026 centers on VS-6766, a dual RAF/MEK clamp, and defactinib, an oral FAK inhibitor. The pair anchors RAMP 201, 202, and 203, targeting low-grade serous ovarian cancer, KRAS/BRAF NSCLC, and KRAS-driven solid tumors. This makes the pipeline narrow but clinically focused.
| Asset | Use | Stage |
|---|---|---|
| VS-6766 | RAF/MEK clamp | Core |
| Defactinib | FAK inhibitor | Combo |
| LUMAKRAS combo | KRAS-G12C | Phase 1/2 |
What is included in the product
Detailed Word Document
Provides a concise, company-specific breakdown of Verastem, Inc.’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Distills Verastem’s 4Ps into a quick, decision-ready snapshot that simplifies strategy review and internal alignment.
Reference Sources
Provides a concise, traceable list of primary and reputable sources that validate Verastem’s market, pricing, and competitive assumptions to speed due diligence.
Place
Needham Massachusetts headquarters
Verastem, Inc. is headquartered in Needham, Massachusetts, and this site serves as its corporate base for development, partnership, and operating decisions. As a clinical-stage oncology company, Verastem runs a lean model with no retail stores or distributor network, so the Needham office anchors a 100% corporate and R&D-led setup. That fits a 2025-style pharma mix built around one HQ, not a sales floor.
Multicenter clinical sites
Verastem, Inc. places its products through multicenter clinical trial networks, with RAMP 201 and RAMP 202 using trial sites to reach patients across geographies. In biopharma, these sites are the main access point before commercial launch, so site quality and enrollment speed shape real market reach. That matters because trial-site execution can affect time to data, and time to data affects future sales timing.
Partner-led commercialization rights
Verastem, Inc. uses a partner-led place strategy for VS-6766: under its Chugai deal, Chugai holds development, commercialization, and manufacturing rights for VS-6766-based products in its territory. That expands market access beyond Verastem, Inc.'s own sales reach and lowers the need for a full in-house launch build. In practice, partner control of supply and local selling can speed entry and widen reach.
Collaborative development channel
Verastem, Inc. uses partnerships as a low-cost route to extend VS-6766 development and reach. The Amgen agreement backs clinical studies of VS-6766 combinations, while Pfizer and Chugai widen scientific access and add external operating reach, which matters for a company still in late-stage development and pre-commercial scale.
- Amgen supports clinical combo work
- Pfizer expands partner reach
- Chugai broadens scientific access
- Partnerships act as indirect market routes
Direct specialty oncology access
Verastem’s place strategy is narrow and clinical: its oncology products are aimed at oncologists, research centers, hospitals, academic medical centers, and trial sites, not consumers. That is typical for a clinical-stage cancer company, where access is driven by specialist prescribing and study enrollment rather than retail distribution.
- Specialist-only access
- Hospital and academic focus
- Trial-center driven reach
This model keeps distribution concentrated where complex cancer care happens and where patient testing, monitoring, and evidence generation are already in place.
Verastem’s Specialist-Led Access Model
Verastem, Inc. uses a narrow place model: its Needham, Massachusetts HQ anchors all corporate control, while access to patients runs through multicenter oncology trial sites. In 2025, this keeps reach specialist-led, not retail-led, and lowers the need for a broad sales footprint. Partner deals, including Chugai rights for VS-6766 in its territory, extend market access without building a full local network.
| Place lever | Current setup |
|---|---|
| HQ | Needham, Massachusetts |
| Access path | Clinical trial sites |
| Partner reach | Chugai territorial rights |
Preview the Actual Deliverable
Verastem, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises.
You're viewing the exact version of the Verastem, Inc. 4P's Marketing Mix Analysis you'll download immediately after checkout, fully complete and ready to use.
This file is the real, high-quality marketing mix report included with your purchase—editable and comprehensive.
Promotion
Clinical trial disclosures
Verastem uses public trial disclosures as a low-cost promotion channel, centered on RAMP 201, RAMP 202, and RAMP 203. These updates keep the pipeline visible and help explain its differentiation in oncology. In 2025, the company still relied on clinical data releases, not mass-market ads, to build awareness and support investor interest.
Scientific data readouts
Verastem, Inc. uses scientific data readouts as its core promotion engine, with oncology efficacy and safety data driving the message. Trial endpoints like ORR, PFS, and duration of response are front and center, plus mutation-specific cohorts that help show who benefits most. In RAMP 201, the combo reported a 44% objective response rate in KRAS-mutant recurrent low-grade serous ovarian cancer.
Partner announcements
Verastem uses partner announcements to widen market visibility, and its links with Chugai, Pfizer, and Amgen give outside validation. In biopharma, collaboration news is a key promo tool because it can lift credibility fast; Verastem’s 3 named large-cap partners do that well.
Investor relations communications
Verastem, Inc. uses investor relations to share pipeline updates, trial milestones, and strategy with shareholders, analysts, and institutions. As a public company, its value is shaped by timely disclosures on clinical progress and capital needs, especially as it advances oncology programs in a market where one delayed trial update can move the stock fast.
- Shares trial status and key milestones
- Explains pipeline and strategy shifts
- Targets shareholders and analysts
- Supports trust with corporate updates
Precision oncology positioning
Verastem, Inc. promotes precision oncology by focusing on biomarker-defined tumors, not broad cancer pools. Its messaging centers on 3 named areas: KRAS, BRAF, and low-grade serous ovarian cancer, which helps the Company stand out from larger oncology peers that market across many indications.
- 3 priority programs sharpen the message
- Biomarkers guide patient selection
- Narrow focus supports clearer differentiation
Verastem’s 2025 Growth Was Driven by Trial Data, Not Ads
Verastem, Inc.’s promotion in 2025 stayed data-led: trial readouts, investor updates, and partner news did the heavy lifting. The sharpest proof point was RAMP 201, where avutometinib + defactinib posted a 44% objective response rate in KRAS-mutant recurrent low-grade serous ovarian cancer. This kept the brand visible without mass-market ads.
| Channel | 2025 signal |
|---|---|
| Trial readouts | RAMP 201, 202, 203 |
| Core metric | 44% ORR |
| Partner messaging | Chugai, Pfizer, Amgen |
Price
No approved commercial price
As of July 2026, Verastem, Inc. has no broadly marketed approved product, so there is no public consumer list price for its lead assets. Pricing is still tied to development-stage programs, where value is set by clinical data, trial progress, and future reimbursement paths. In this phase, the market price is effectively undisclosed.
Trial access not patient priced
Clinical trial access in Verastem, Inc. RAMP studies is sponsor funded, so patients do not pay a retail drug price. The economic model is research access, not commercial sale, which keeps out-of-pocket cost at $0 for the study drug. That fits the usual trial setup: the sponsor covers the investigational product, while pricing only starts after approval and launch.
Future specialty oncology pricing
If approved, VS-6766-based therapies would likely price in the specialty oncology band, where many targeted cancer drugs launch above $100,000 a year. Biomarker targeting and combination use usually justify premium pricing, but they also lift total treatment cost. Reimbursement will hinge on payor coverage, real-world outcomes, and evidence of clinical value.
Partner economics undisclosed
Partner economics for Verastem, Inc. are not fully public, so the exact price split is unclear. Revenue could still be shaped by milestones, royalties, and shared development value from Chugai, Pfizer, and Amgen links, but the contract terms are undisclosed.
That matters because even a single milestone can move near-term cash, while royalties can support longer-term sales. Without a public price schedule, the best read is that economics are relationship-based, not fixed and fully transparent.
- Exact price structure is undisclosed
- Milestones may affect cash flow
- Royalties may support future revenue
- Shared development value is possible
Value based market access
Verastem, Inc. uses value based market access because oncology prices are tied to survival gain, safety, and unmet need. Its mutation-specific studies, including the RAMP-201 program in recurrent low-grade serous ovarian cancer, support a pay-for-value case rather than broad volume selling.
Any launch price would likely hinge on response data and payer talks, not unit count. In a niche cancer segment, even a 40% plus response rate can matter more than scale if reimbursement is secured.
- Value linked to outcomes.
- Mutation-specific trials support pricing.
- Payer access drives launch success.
Verastem Pricing: $0 in Trial, Potentially $100K+ at Launch
As of July 2026, Verastem, Inc. has no approved product, so there is no public list price. RAMP study access is sponsor funded, so patients pay $0 for the investigational drug. If launched, VS-6766 could fit specialty oncology pricing, often above $100,000 a year, with reimbursement tied to outcomes and payer talks.
| Item | Price view |
|---|---|
| Approved product | No public price |
| Trial access | $0 patient cost |
| Likely launch band | Above $100,000/yr |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.